<DOC>
	<DOCNO>NCT01062048</DOCNO>
	<brief_summary>The objective survey : 1 ) To examine safety/efficacy profile Januvia Korean participant , 2 ) To identify factor might influence safety efficacy profile Januvia Korean participant . Post-marketing survey consider applicable clinical trial thus result survey post conclusion . The result submit public health official require applicable national international law .</brief_summary>
	<brief_title>Januvia Re-examination Study ( MK-0431-181 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Type 2 Diabetes Mellitus Treated With Januvia within local label first time Contraindication Januvia accord local label Treated Januvia contract enrollment period Inclusion criterion longterm surveillance Treated Januvia equal 24 week</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>